Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Onapristone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR known ✓ | P06401 | 13/20 | 1.00 |
| ▸ | NR3C1 | P04150 | 11/20 | 1.00 |
| ▸ | AR | P10275 | 8/20 | 1.00 |
| ▸ | NR3C2 | P08235 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.69 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.69 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.69 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.69 |
| ▸ | ESR1 | P03372 | 3/20 | 0.69 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.69 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.69 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.69 |
| ▸ | LMNA | P02545 | 2/20 | 0.69 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.69 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.69 |
| ▸ | TP53 | P04637 | 1/20 | 0.69 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.69 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.69 |
| ▸ | THPO | P40225 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Onapristone SCHEMBL6670566 | 1.00 | PGR (1.00) | PGRNR3C1ARNR3C2CYP3A4 | |
| Onapristone SCHEMBL9170610 | 1.00 | PGR (1.00) | PGRNR3C1ARNR3C2CYP3A4 | |
| Onapristone SCHEMBL8740 | 1.00 | PGR (1.00) | PGRNR3C1ARNR3C2CYP3A4 | |
| Onapristone SCHEMBL14870640 | 1.00 | PGR (1.00) | PGRNR3C1ARNR3C2CYP3A4 | |
| Onapristone SCHEMBL13625154 | 1.00 | PGR (1.00) | PGRNR3C1ARNR3C2CYP3A4 | |
| Onapristone SCHEMBL5596231 | 1.00 | PGR (1.00) | PGRNR3C1ARNR3C2CYP3A4 | |
| Onapristone SCHEMBL24910667 | 1.00 | PGR (1.00) | PGRNR3C1ARNR3C2CYP3A4 | |
| Onapristone SCHEMBL10625426 | 1.00 | PGR (1.00) | PGRNR3C1ARNR3C2CYP3A4 | |
| Onapristone SCHEMBL21740378 | 1.00 | PGR (1.00) | PGRNR3C1ARNR3C2CYP3A4 | |
| Onapristone SCHEMBL9558898 | 1.00 | PGR (1.00) | PGRNR3C1ARNR3C2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1738752-A1 | Pharmaceutical combinations comprising cis-retine acid | Schering Aktiengesellschaft (DE) | 2007-01-03 | — | — | EP | claimed |
| EP-1738752-A1 | Pharmaceutical combinations comprising cis-retine acid | Schering Aktiengesellschaft (DE) | 2007-01-03 | — | — | EP | disclosed |
| EP-1641458-A2 | PHARMACEUTICAL COMBINATIONS OF PHTHALAZINE VEGF INHIBITORS AND BENZAMIDE HDAC INHIBITORS | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-04-05 | — | — | EP | disclosed |
| US-20050054647-A1 | New pharmaceutical combination | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-03-10 | — | — | US | disclosed |
| WO-2004058234-A2 | PHARMACEUTICAL COMBINATIONS OF PHTHALAZINE VEGF INHIBITORS AND BENZAMIDE HDAC INHIBITORS | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-07-15 | — | — | WO | disclosed |
| EP-0616812-B1 | Combination with anti-hormonal compounds and binding molecules for the treatment of cancer | BERLEX BIOSCIENCES (US) | 1999-11-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054647-A1 | New pharmaceutical combination | VEGFA, INHA, PGF | PGR 116/4885NR3C1 1117/4885AR 300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.